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Abstract. Polyphenols are a large and heterogeneous group of 
compounds widely distributed in fruits, vegetables, cereals and 
their products such as coffee or wine. These bioactive compounds 
can ameliorate our health by improving certain risk factors, 
especially the cardiovascular ones. Thus, many investigations 
have focused on the effects of some polyphenols and polyphenol-




      Cardiovascular diseases (CVD), including coronary heart disease, 
cerebrovascular disease, rheumatic heart disease and other disorders of the 
heart and blood vessels, are the leading cause of mortality and disability in 
developed countries. According to the World Health Organization (WHO), 
31% of all deaths in the world are attributed to CVD, and more than 75% 
occur in low and middle-income countries [1]. Some risk factors for CVD 
 
Correspondence/Reprint request: Dr. Tresserra-Rimbau, Department of Nutrition and Food Science, XaRTA, 
INSA-UB, Pharmacy School, University of Barcelona, Avda. Joan XXIII, s/n, 08028 Barcelona, Spain  
E-mail annatresserra@ub.edu 
Anna Tresserra-Rimbau & Rosa M. Lamuela-Raventós 18 
are intrinsic and cannot be modified: sex, age, race and genetic 
predisposition. However, many of them are related to lifestyle and dietary 
habits and they are also related to each other: stress, obesity, type-2 
Diabetes Mellitus (DM) or insulin resistance, dyslipidemia, and 
hypertension (Fig.1). In addition to these classic risk factors, there are 
other non-classic factors including homocysteine, fibrinogen, 
lipoprotein(a), low-density lipoprotein (LDL) particle size and high-
sensitivity C-reactive protein (CRP) [1]. Preventive measures such as 
smoking cessation, following a healthy diet, being physically active, and 
regular screenings may help to lower cardiovascular risk [2]. In fact, 
prevention, even more than treatment, is a priority for the public health 
agencies, which make huge efforts to raise awareness in the population 
with the aim of reversing this trend [3]. 
 The Mediterranean Diet (MedDiet), as well as other diets rich in fruits 
and vegetables such as the Dietary Approaches to Stop Hypertension 
(DASH) dietary pattern, the US Department of Agriculture (USDA) food 
pattern, or the American Heart Association (AHA) diet, are an effective 
way to reduce cardiovascular risk factors due to their high content in 
vitamins, minerals, fiber, and mono and polyunsaturated fatty acids, and 
other bioactive compounds [4]. The latter, also known as phytochemicals 
or phytonutrients, have the capacity to alter biochemical reactions and 
consequently affect human health [5]. Polyphenols are one of these 
bioactive compounds. They are a large and heterogeneous group of 
molecules mainly found in fruits, vegetables, cereals and their products. 
Up to now, hundreds of different polyphenolic structures have been 
described in many foods and beverages. Polyphenols have received great 
attention among nutritionists, consumers and researchers since it has been 
proved that they have beneficial effects on our health. However, due to the 
great variety of existing structures, different polyphenol subgroups may 
differ significantly in stability, bioavailability and physiological functions 
related to human health. Thus, it is difficult to study their health effects, 
their bioavailability or their mechanisms of action. For this reason, many 
studies have focused only in one polyphenol group or even in one 
polyphenol.  Globally, polyphenols seems to improve certain CVDs risk 
factors such as insulin resistance, inflammation biomarkers, or blood 
pressure (BP), among others [6]. Additionally, polyphenols have been 
associated to a decreased risk of certain cancers, neurodegenerative 
diseases, diabetes and osteoporosis [7]. 
 In this chapter, we summarize recent findings about the effects of 
polyphenol and polyphenol-rich foods intake on cardiovascular risk factors, 
especially BP and dyslipidemia.  
Benefits of polyphenol intake on the cardiovascular system 19 
 
 
Figure 1. Modifiable cardiovascular risk factors. 
 
1. Polyphenols: General structure and classification 
 
 Polyphenols are one of the most numerous and widely distributed groups 
of natural products in the plant kingdom. Since polyphenols are secondary 
metabolites of plants, they are naturally found in fruits, vegetables, cereals 
and beverages, mainly coffee, tea, wine, fruit juices and beer [8]. This group 
of compounds constitutes the main source of antioxidants in our diet. Total 
dietary polyphenol intake is estimated to be around 1 g/day, 10 times higher 
than that of vitamin C and 100 times higher than intakes of vitamin E and 
carotenoids [9].  
 More than 8000 phenolic structures are currently known. The structure 
of polyphenols consists of at least one aromatic ring carrying one or more 
hydroxyl moiety. The diversity and wide distribution of polyphenols in 
plants have led to different classifications, for instance, by their source of 
origin, biological function, or chemical structure [8]. However, the most 
common way to categorize them by the chemical structure of the aglycones 
(according to the number of phenol rings they bear and the structural 
elements that bind these rings). This broadly accepted classification 
divides polyphenols into two main groups: flavonoids and nonflavonoids 
[6].  
 Flavonoids have a C6-C3-C6 structure, consisting on a skeleton of two 
benzene rings (A and B) connected by a three-carbon chain forming a closed 
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pyran ring with the benzene A ring. Flavonoids are divided in subgroups 
according to the oxidation of the central ring and the type of substituents in 
the heterocyclic ring. These subgroups are flavones, flavonols, flavan-3-ols 
(and their polymeric forms, proanthocyanidins), flavanones, anthocyanidins, 
and isoflavones (Fig. 2).  
 The nonflavonoid group is classified according to the number of carbons 
they possess, and include phenolic acids, stilbenes, lignans and other 
polyphenols that are only found in smaller amounts such as simple phenols, 
hydrolysable tannins, acetophenones, phenilacetic acids, cinnamic acids or 
seicoiridoids. Phenolic acids comprise hydroxycinnamic acids, 
hydroxybenzoic acids, hydroxyphenylacetic acids, and 
hydroxyphenylpropanoic acids [10]. 
 Besides presenting a huge variety of structures, polyphenols are usually 
attached to various carbohydrates and organic acids, as well as to other 
polyphenols. In plants, they are usually glycosylated, mainly with glucose or 
rhamnose and, less frequently, to galactose, arabinose, xylose, glucuronic 
acid or other sugars (Fig. 3). The number of glycosyl moieties usually varies 




Figure 2. Classification of polyphenols. 
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Figure 3. Example of quercetin metabolites from plants and biological fluids. 
 
2. Distribution of polyphenols in food 
 
 As stated above, fruits, beverages and vegetables constitute the main 
sources of polyphenols. Fruits like apples, grapes, and berries contain up to 
200–300 mg polyphenols per 100 g fresh weight, whereas a glass of red 
wine or a cup of tea or coffee contains about 100 mg polyphenols [12]. 
Herbs and spices often contain very high level of phenolic compounds but 
their consumption is limited to low amounts, therefore their contribution to 
total dietary intake is low [13]. 
 Plant polyphenol composition is highly variable. Some of the 
compounds, such as quercetin, are ubiquitous, whereas others are more 
specific from particular foods (e.g., epigallocatechin gallate in green tea, 
isoflavones in legumes, flavanones in citrus fruit, or phloridzin in apples) 
[14]. 
 Numerous factors affect the polyphenol content of plants. For example, 
the phenolic content of the skin of a given fruit is higher than that of the pulp 
since plants synthesize polyphenols as a mechanism of defense against 
Anna Tresserra-Rimbau & Rosa M. Lamuela-Raventós 22 
external agents. For this reason, fruit and vegetables from organic agriculture 
have also higher content of polyphenols than those from traditional 
agriculture [15]. Maturity, genetic factors, environment (sun exposure, 
rainfall), storage or manipulation will also influence the concentration of 
polyphenols. The degree of ripening has different effects depending on the 
polyphenol class: in general, phenolic acid concentrations decrease during 
ripening, whereas anthocyanin concentrations increase. Finally, the cooking 
method also have great influence: the phenolic concentration of foods 
decreases while their bioavailability is higher compared to raw foods 
[16,17].   
 Flavonols, one of the flavonoid subgroups, are the most abundant 
polyphenols in food. They are present in onions, spinach, berries, tea, dark 
chocolate, vegetables, nuts, and in most of the spices. The richest sources 
of flavanones are citrus fruits like grapefruit, orange, and lemon. Flavones 
are notably present in celery, red chicory, artichoke, black olives, and 
citrus fruits, whereas isoflavones are found in soy foods. Anthocyanins are 
typical of red dark-colored fruits and their products: berries, cherry, black 
olives, or red wine. Finally, dark chocolate, berries, nuts, tea and red wine 
are important sources of flavanols and their polymers, procyanidins [13]. 
 Although flavonoids have traditionally been the most broadly studied 
group, nonflavonoids also contribute significantly to our polyphenol 
dietary intake. Phenolic acids, including hydroxycinnamic acids and 
hydroxybenzoic acids, are widely distributed in foods. The latter is present 
in higher amounts in chestnut, raspberry, pomegranate juice, and 
blackberry. Hydroxycinnamic acids are mostly found in coffee, artichoke, 
prune, chicory, blueberry, black olives, plum, and sweet cherry. Stilbenes 
and lignans are characteristic of red wine and seeds, respectively [13]. The 
most known and studied stilbene is trans-resveratrol, which is reported to 
have multiple health effects [18–20]. Finally, olive oil contains several 
simple phenols such as hydroxytyrosol and tyrosol [21]. 
 Analysis of polyphenols in food is a highly complex process that 
requires multiple factors to be considered: food matrix, interferences, the 
variable solubility of the compounds, temperature, extraction time, and 
concentration levels that varies from traces to milligrams. Low 
temperatures, organic solvents, lyophilization and working under UV-free 
light conditions are extensively used methods to prevent the oxidation of 
polyphenolic compounds [22].  
 When the main objective is a detailed phenolic profile, mass 
spectrometry coupled to liquid chromatography is the most common 
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technique for identification and quantification, although in some cases gas 
chromatography and capillary electrophoresis can also be used. To 
quantify total polyphenols or those of a given group, spectrophotometric 
methods are useful and simpler. The Folin-Ciocalteu (F-C) method has 
been extensively used to determine total polyphenol content, whereas other 
more specific reactives are used to determine proanthocyanidins, 
hydrolyzable tannins, anthocyanidins, and flavan-3-ols [10,22]. 
 
3. Bioavailability and metabolism of polyphenols 
 
 Bioavailability is the proportion of the nutrient that is digested, 
absorbed and metabolized so that is available at the site of action [23]. 
Therefore, it is important to know, not only how much polyphenols we 
intake, but in which proportion they are available and reach target 
tissues.  
 The chemical structure of polyphenols determines their absorption 
and the structure of the metabolites circulating in the plasma. Given the 
huge variety of existing phenolic structures, the biological properties of 
polyphenols greatly differs from one polyphenol to another. Thus, the 
most abundant polyphenols in our diet are not necessarily those leading 
to the highest concentrations of active metabolites in our tissues [24]. 
Absorption of polyphenols also depends on fat intake, food matrix, dose, 
intestinal transit, and other factors [23]. Recently, emerging findings 
suggested that microbiota plays a crucial role in the metabolism of 
polyphenols and, at the same time, polyphenols contribute to the 
maintenance of gut health by the modulation of the gut microbial 
balance enhancing the growth of beneficial bacteria while competitively 
excluding pathogenic bacteria, exerting prebiotic-like effects. Both the 
formation of bioactive polyphenol-derived metabolites by the 
microbiota and the modulation of colonic microbiota by polyphenols 
contribute to host health benefits [25–28]. For instance, equol, 
enterolactone and enterodiol are produced by the colonic microflora 
after consumption of soy (or other isoflavones-rich food) and equol 
have greater phytoestrogenic properties than those of the original 
isoflavone [29].  
 Generally, the metabolism of polyphenols takes place as follows  
(Fig. 5): after the ingestion, some polyphenols, aglycones and 
anthocyanins, are directly absorbed in the stomach and small intestine. 
Esters, glycosides and polymers need to be hydrolyzed by intestinal 
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enzymes or the colonic microflora. Once absorbed, polyphenols undergo 
some degree of phase I and II metabolism in the enterocytes as 
methylation, sulfation and/or glucuronidation depending on the nature 
of the substrate and the dose. Polyphenol metabolites enter to the 
bloodstream by the portal vein to the liver, where they may be subjected 
to more conjugations. Then, metabolites travel through the bloodstream 
again attached to carriers such as albumin until they are excreted. There 
are two ways of excretion that depends on the molecular weight. The 
heavier compounds are usually eliminated as bile components. Back in 
the intestine (enterohepatic circulation), some of them are deconjugated 
and regenerated by gut microbial enzymes and are reabsorbed. The 
unabsorbed ones are eliminated via feces. The lighter polyphenols are 




Figure 4. Absorption and metabolism of dietary polyphenols in humans. 
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4. Polyphenols and health 
 
 Numerous epidemiological and human intervention studies have 
shown that polyphenol intake may protect against cardiovascular and 
neurodegenerative diseases, some cancers, insulin resistance, and obesity, 
among others [6,7,30]. However, most of the evidence on the beneficial 
effects of dietary polyphenols is derived from in vitro and/or animal 
studies and using concentrations much higher than those achievable 
through the diet. Thus, translation of these results to humans needs to be 
tested. Moreover, the generally used compounds for in vitro studies are 
polyphenol aglycones or their sugar conjugates instead of the physiological 
metabolites [31].  
 Normal physiological processes such as respiration and metabolic 
reactions that take place in our body, as well as other exogenous factors, 
produce reactive oxygen species (ROS). As defense mechanisms, our body 
has endogenous antioxidants to eliminate the ROS since these molecules 
can bind to DNA, lipids and proteins, altering their stability and leading to 
various diseases, such as diabetes, Alzheimer's, Parkinson's, cancer, CVD 
related diseases and respiratory diseases. Polyphenols can reduce oxidative 
stress and delay ageing [32–34]. 
 The effect of polyphenols as chemopreventive agents has been 
extensively demonstrated in animal models but is still very limited in 
humans and there is only promising data regarding regular consumption of 
green tea and its main polyphenol epigallocatechin gallate and oral and 
prostate cancer development [6]. It has been hypothesized that polyphenols 
may act by blocking the initial stages of the disease by modulating the 
expression of cytochrome P-450 enzymes involved in the activation of 
carcinogens and limiting the formation of initiated cells by stimulating 
DNA repair. In promotion stages, these compounds slow or stop tumor 
growth by inhibiting the expression of genes involved in tumor 
proliferation or inducing apoptosis of malignant cells. In progression 
stages they can inhibit angiogenesis and limit tumor invasion [7,35,36].  
 The effect of polyphenols in neurodegenerative diseases has usually 
been performed in animal models and neuronal cells. Polyphenols like 
resveratrol, proanthocyanidins, epicatechin, catechin and ferulic acid, as 
well as polyphenols from different foods have shown to reduce β-amyloid 
peptides in mice, which are involved in the pathogenesis of Alzheimer's 
disease [37–39]. Studies carried out in humans showed an improvement of 
memory in old people with mild cognitive problems. These compounds 
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interfered in the generation and aggregation of β-amyloid peptides [40]. 
Flavonoid intake was also associated with better cognitive ability in 
humans [41]. However, it is unclear whether polyphenols directly interact 
with neural systems because it is unknown if all polyphenols are able to 
reach the brain [37]. Nowadays, we only know that some metabolites from 
gallocatechin gallate epicatechin and anthocyanins are able to cross the 
blood-brain barrier in animals [42,43].  
 
4.1. Cardiovascular effects of phenolic compounds 
   
 A large number of epidemiological studies and some human 
intervention studies have associated the consumption of polyphenols with a 
decreased risk of CVD. Nowadays, the strongest evidence for the efficacy 
of polyphenols reducing biomarkers of cardiovascular risk comes from 
flavan-3-ols-rich foods, especially cocoa and tea [6,44,45]. Other 
prospective studies associated the intake of anthocyanins and flavanones 
with a lower risk of CVD  and total mortality [46,47].  
 The protective effect of polyphenols may be explained by the 
improvements they confer on various risk factors that are much more 
effective than treating the CVD itself. Indeed, it has been shown that 
polyphenols improve endothelial function by improving parameters such 
as LDL cholesterol, platelet aggregation, invasion and proliferation of 
smooth muscle cells in the arterial wall, nitric oxide (NO) and some 
markers of inflammation [7,48]. 
 The endothelium is the innermost layer of the blood vessel walls. 
Endothelial cells, in response to various stimuli, release molecules that are 
responsible for maintaining normal endothelial function. When the balance 
is disrupted the homeostatic functions of the endothelium are altered and 
the process of atherosclerosis, a chronic inflammation of large artery walls, 
starts. Hypertension, high LDL cholesterol levels or low high-density 
lipoprotein (HDL) cholesterol levels, diabetes and smoking are risk factors 
for atherosclerosis [49,50]. 
 Hypertension is a public health issue that affects more than 1 billion 
people worldwide, causing 7.6 million deaths annually. Hypertension is 
diagnosed when systolic blood pressure (SBP) is permanently greater than 
140 mm Hg and/or diastolic blood pressure (DBP) is greater than 90 mm 
Hg [51].  
 Several human intervention studies have related polyphenol-rich foods 
with a decrease in BP and other related parameters. Results from the most 
recent studies (from 2010 to 2015) are summarized in Table 1. 
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 A possible mechanism by which polyphenols decrease BP is by 
enhancing NO production. In vitro experiments with isolated arteries showed 
that polyphenols increased endothelial NO formation and caused NO-
mediated endothelium-dependent relaxations [67].  
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 Metabolic syndrome (MS) is a metabolic disorder that consists of a 
combination of multiple cardiovascular risk factors: obesity, hypertension, 
dyslipidemia and hyperglycemia. The consumption of polyphenol-rich 
foods can prevent MS through their protective effect on chronic 
inflammation linked to obesity, insulin resistance, dyslipidemia, and 
hypertension [68].  
 Some in vitro, animal and human studies have shown that polyphenols 
help to control obesity by reducing fat absorption in the intestinal tract, 
activating thermogenesis and modulating the hormonal response that 
regulates food intake and satiety [69]. 
 Consumption of cocoa has shown to reduce MS by improving insulin 
resistance, endothelial function and levels of NO. These effects have been 
confirmed in multiple literature reviews and meta-analyzes [70]. Similar 
results were observed with the consumption of green tea [71], olive oil 
[72] and other polyphenol-rich foods.  
 Polyphenols could also help to reduce diabetes through different 
mechanisms. They can inhibit glucose absorption in the small intestine and 
its reabsorption in the liver, gluconeogenesis, adrenergic stimulation of 
glucose consumption, or stimulation of insulin release by pancreatic beta 
cells. For example, polyphenols from cinnamon, resveratrol, isoflavones, 
and polyphenols from tea, cocoa and grape seeds improve insulin 
sensitivity, the hormone that regulates plasmatic glucose levels [7,69]. 
 
5. Polyphenol intake and its effects in the PREDIMED cohort 
 
 In the 60s, the Mediterranean diet (MedDiet) was defined for the first 
time as the dietary pattern followed by Cretan, Greek and Southern Italian 
citizens. According to Ancel Keys, this diet was low in saturated fat and 
high in vegetable oils. The MedDiet has deserved much attention in the 
past decades due to its numerous beneficial effects in our health. The 
original definition has evolved to a more extensive one. Nowadays, in 
general terms, we can consider that guidelines to follow a MedDiet include 
high intakes of vegetables including leafy green vegetables, fruits, cereals, 
nuts, legumes and extra virgin olive oil, moderate intakes of fish, meat, 
dairy products and red wine, and low intakes of eggs and sweets [69]. 
 The PREDIMED study (PREvención con DIeta MEDiterránea, 
ISRCTN35739639) was a prospective, randomized, multicentric and 
controlled trial aimed to assess the health benefits of a traditional 
Mediterranean diet (MedDiet) in the primary prevention of cardiovascular 
diseases [70,71]. The study lasted 9 years, from 2004 to 2013, and 
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included 7447 elderly participants at high cardiovascular risk. Volunteers 
were recruited through primary health care centers from 8 different 
Spanish regions and they were randomized to one of the following 
nutritional intervention groups: Mediterranean diet supplemented with 
extra virgin olive oil (MedDiet -EVOO), Mediterranean diet supplemented 
with nuts (MedDiet -nuts), and a control group which followed a low-fat 
diet according to the recommendations of the American Heart Association 
(AHA) [72]. 
 After a median of 4.8 years of follow-up, an external scientific 
committee advised to finish the study due to the marked differences 
between the MedDiet groups and the control group. Results revealed that 
both MedDiet groups had 30% less incidence of CVD events than the 
control group. Specifically, the adjusted  hazard ratio (HR) were 0.70 (95% 
CI 0.54-0.92) and 0.72  (95% CI 0.54-0.96) when comparing the MedDiet 
-EVOO and the MedDiet -nuts with the control group [73].  
 Within the PREDIMED, and after only 3 months of intervention, it 
was demonstrated that improving a diet towards a MedDiet pattern 
decreased LDL cholesterol, glucose, BP, and biomarkers of inflammation 
[70,74]. After one year of intervention, results showed that both MedDiet 
(MedDiet -VOO and MedDiet -nuts), but not the control diet, were able to 
revert the metabolic syndrome [75,76] and to increase non enzymatic 
antioxidant capacity of plasma [77], as well as decrease cellular and 
circulating inflammatory biomarkers related to atherogenesis [78]. Other 
investigations were aimed to assess the beneficial effects of the MedDiet 
on obesity [79,80], cognitive impairment [81], hyperuricemia [82], and 
type-2 diabetes [83]. MedDiet also delayed the progression of internal 
carotid intima-media thickness and plaque height [84] and reduced 
oxidative damage to lipids and DNA in individuals with metabolic 
syndrome [85]. These results provide further evidence to recommend a 
MedDiet pattern supplemented with nuts and olive oil to decrease CVDs 
risk factors, especially when these recommendations are addressed to 
elderly people at high CVDs risk. 
 Beyond its main objective, the PREDIMED study has been the nest of 
other numerous sub-studies involving many exposure variables others than 
MedDiet and CVD-related outcomes. Polyphenols and polyphenol-rich 
foods have been one of the studied exposure variables. The concentration 
of total polyphenols in spot urine samples as a biomarker of total 
polyphenol intake [86] was negatively associated with BP levels and 
prevalence of hypertension in a cross-sectional sub-study of 589 
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participants from the PREDIMED trial [87]. This effect was mediated by 
the increase of nitric oxide (NO) in plasma [88]. Valls-Pedret et al. also 
found that a high consumption of antioxidant-rich foods such as virgin 
olive oil, coffee, walnuts or wine, and a high intake of polyphenols were 
associated with better cognitive function [89]. Total polyphenol intake 
assessed using yearly food frequency questionnaires and the Phenol-
explorer database was associated with cardiovascular mortality and events, 
and all-cause mortality. From them, lignans, flavanols, and 
hydroxybenzoic acids were associated with decreased CVDs risk [90] 
while high intakes of stilbenes and lignans showed a reduced risk of 
overall mortality [91]. 
 Regarding polyphenol-rich foods, moderate red wine consumption 
was associated with a lower prevalence of the metabolic syndrome and 
some of its components: increased waist circumference, low HDL-
cholesterol, high BP, and high fasting plasma glucose concentrations 
[92]. Resveratrol in urine, as a biomarker of wine intake, was also 
inversely associated with cardiovascular risk factors: blood lipid profiles, 
fasting blood glucose, and heart rate [93]. Finally, consumption of extra 
virgin olive oil decreased CVD, atrial fibrillation and carotid intima-
media thickness [94–96], while consumption of nuts decreased adiposity 




 Polyphenols are bioactive compounds mainly found in fruits, 
vegetables, cereals and their products. Several studies have demonstrated 
that polyphenols and polyphenol-rich foods can improve cardiovascular 
health through different mechanisms. However, some results are 
contradictory and more mechanisms still need to be elucidated so future 
research have to substantiate these findings in order to stablish dietary 
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